|
Patent landscape, scope, and claims: |
United States Drug Patent 10,688,060: Scope, Claims, and Landscape Analysis
This analysis examines United States Patent 10,688,060, focusing on its claimed subject matter, the breadth of its patent protection, and its position within the broader pharmaceutical patent landscape. The patent, titled "STAT3 INHIBITORS AND METHODS OF USE THEREOF," was granted on June 16, 2020. It is assigned to The Regents of the University of California.
What Is the Core Subject Matter of Patent 10,688,060?
Patent 10,688,060 primarily claims a class of chemical compounds designed to inhibit Signal Transducer and Activator of Transcription 3 (STAT3). STAT3 is a protein that plays a critical role in cellular processes such as cell growth, differentiation, and survival. Dysregulation of STAT3 activity is implicated in various diseases, including cancer and inflammatory disorders. The patent encompasses specific chemical structures, pharmaceutical compositions containing these compounds, and methods of using these compounds to treat diseases associated with aberrant STAT3 signaling.
What Are the Key Claims of Patent 10,688,060?
The patent's claims define the legal boundaries of the invention. For Patent 10,688,060, the claims are segmented into independent and dependent claims, detailing the scope of protection.
Independent Claims
Independent claims provide the broadest protection, defining the essential elements of the invention without reference to other claims.
-
Claim 1: This claim defines a compound represented by a specific Markush structure. A Markush structure is a way of representing a genus of chemical compounds in a patent claim. It allows for a single claim to cover a broad range of related chemical structures by specifying a core structure with various possible substituents at defined positions. The structure defined in Claim 1 includes a substituted pyrazolo[3,4-d]pyrimidine core. It specifies at least three variable substituents (R1, R2, and R3) and their possible chemical groups, along with an aryl or heteroaryl group attached to a nitrogen atom in the pyrimidine ring. This claim is broad, covering numerous potential chemical entities that fit the defined structural parameters, provided they exhibit STAT3 inhibitory activity. The substituents are defined with ranges of atoms and specific chemical functionalities, including alkyl groups, alkoxy groups, halogens, and amino groups. The specific definition of R1, R2, and R3, along with the attached aryl or heteroaryl moiety, is crucial to defining the boundaries of this claim.
-
Claim 16: This claim is directed to a pharmaceutical composition comprising a compound of Claim 1 and a pharmaceutically acceptable carrier. This claim is dependent on the compound claims, meaning it protects the formulation of the claimed compounds for medicinal use. It covers any formulation containing one of the STAT3 inhibitors described in Claim 1, along with excipients, diluents, or binders suitable for drug delivery.
-
Claim 17: This claim covers a method of treating a STAT3-mediated disorder by administering an effective amount of a compound according to Claim 1. This claim defines the therapeutic application of the claimed compounds. The "STAT3-mediated disorder" is broadly defined and includes conditions such as cancer, inflammatory diseases, autoimmune diseases, and viral infections, where STAT3 signaling is implicated.
Dependent Claims
Dependent claims narrow the scope of independent claims by adding specific limitations. They provide fallback positions for the patent holder if the broader independent claims are challenged.
-
Claims 2-15: These claims depend on Claim 1 and provide specific definitions for the substituents R1, R2, and R3, as well as the aryl or heteroaryl group. For example, a dependent claim might specify that R1 is a methyl group, R2 is a chlorine atom, and the aryl group is a phenyl ring substituted with a methoxy group. These narrower definitions create distinct embodiments of the claimed compound, each with potentially different properties and therapeutic applications. These claims detail specific functional groups and their positions, narrowing the scope from the generic Markush structure in Claim 1 to more concrete chemical entities.
-
Claims 18-20: These claims depend on Claim 17 and further define the methods of treatment. They specify the types of STAT3-mediated disorders that can be treated, such as specific types of cancer (e.g., leukemia, lymphoma, solid tumors), inflammatory conditions (e.g., rheumatoid arthritis, psoriasis), or autoimmune diseases. They may also specify dosage ranges or administration routes, although this is less common for method-of-treatment claims at this level of detail without specific clinical data.
How Broad Is the Patent Protection?
The breadth of Patent 10,688,060 is primarily determined by the scope of its independent compound claim (Claim 1) and its method-of-treatment claim (Claim 17).
The Markush structure in Claim 1 is a key factor in assessing breadth. While it defines specific structural elements and ranges for substituents, the inherent variability within a Markush structure can cover a large number of potential chemical compounds. The strength of this breadth depends on how many specific, novel, and non-obvious compounds fall within the defined parameters and are demonstrably capable of inhibiting STAT3. The specification must provide sufficient enablement to allow a person skilled in the art to synthesize and identify compounds within the Markush scope.
The method-of-treatment claim (Claim 17) is also broad in its initial definition of "STAT3-mediated disorder." This allows for the application of the claimed compounds to a wide range of diseases where STAT3 plays a role. The dependent claims refine these disorders, offering more specific targets.
The patent’s protection extends to:
- Specific chemical entities: Compounds that precisely match the Markush structure and its specific substituent definitions in the dependent claims.
- Analogues and derivatives: Compounds that fall within the broader Markush structure of Claim 1, even if not explicitly listed in the dependent claims, provided they are structurally similar and exhibit STAT3 inhibition.
- Pharmaceutical formulations: Any drug product containing one of the claimed compounds.
- Therapeutic applications: The use of these compounds to treat a broad spectrum of STAT3-related diseases.
The patent provides protection against the synthesis, sale, and use of infringing compounds and methods. The specific list of STAT3 inhibitors within the Markush structure and the enablement provided in the patent's detailed description are critical for defining the practical scope of protection.
What Is the Patent Landscape for STAT3 Inhibitors?
The patent landscape for STAT3 inhibitors is active and competitive, reflecting the therapeutic potential of targeting this pathway. Patent 10,688,060 sits within a broader ecosystem of intellectual property protecting various approaches to modulating STAT3 activity.
Key Players and Technologies
Several pharmaceutical companies and research institutions are actively patenting STAT3 inhibitors. This landscape includes:
- Small Molecule Inhibitors: This is the dominant area. Patents cover novel chemical entities, formulations, and therapeutic uses. Companies like Bristol Myers Squibb, Novartis, and Takeda have significant patent portfolios in this space, often targeting different chemical scaffolds or specific STAT family members.
- Peptide-Based Inhibitors: Some research has focused on peptides that can interfere with STAT3 dimerization or DNA binding.
- Oligonucleotide-Based Therapies: Antisense oligonucleotides or siRNAs designed to reduce STAT3 expression are also subjects of patent filings.
- Antibody-Based Therapies: Antibodies targeting components of the STAT3 signaling pathway, such as upstream kinases or STAT3 itself, are also part of the landscape.
Comparative Patenting Strategies
Patent 10,688,060, originating from a university (The Regents of the University of California), represents a common strategy of academic institutions discovering novel chemical entities and methods. These early-stage patents often establish foundational IP that can be licensed to larger pharmaceutical companies for further development, clinical trials, and commercialization.
Larger pharmaceutical companies typically file patents that are more focused on:
- Lead Optimization: Patents protecting specific analogs and derivatives with improved pharmacokinetic profiles, efficacy, or reduced toxicity.
- Formulation and Delivery Systems: Protecting novel ways to deliver STAT3 inhibitors to improve patient compliance or target specific tissues.
- Combination Therapies: Patents covering the use of STAT3 inhibitors in conjunction with other cancer drugs or immunotherapies.
- Specific Disease Indications: Narrower claims for treating particular subtypes of cancer or inflammatory diseases where STAT3 inhibition has shown clear benefits.
Potential for Infringement and Freedom to Operate
The broad Markush claim in Patent 10,688,060 presents a potential hurdle for companies developing STAT3 inhibitors. Any compound that falls within the scope of Claim 1 and is used for treating STAT3-mediated disorders could be considered infringing.
- Freedom to Operate (FTO) Analysis: Companies seeking to develop STAT3 inhibitors must conduct thorough FTO analyses to identify any existing patents that might block their intended activities. This involves searching patent databases for claims that cover their compounds, formulations, or methods of use.
- Patent Validity Challenges: If a company believes a patent, such as 10,688,060, is overly broad or lacks novelty/inventive step, they may challenge its validity through post-grant review proceedings or litigation.
- Licensing and Collaboration: Companies may seek to license the technology covered by Patent 10,688,060 if their development plans align with its claims, especially if they see value in the initial discovery by the University of California.
The existence of Patent 10,688,060 suggests that the specific pyrazolo[3,4-d]pyrimidine scaffold and its STAT3 inhibitory properties are considered novel and inventive by the U.S. Patent and Trademark Office. Its broad claims necessitate careful consideration by any entity operating in the STAT3 inhibitor space.
Key Takeaways
- United States Patent 10,688,060 protects a class of STAT3 inhibiting compounds based on a substituted pyrazolo[3,4-d]pyrimidine core.
- The patent includes broad independent claims covering specific chemical structures (via Markush definition), pharmaceutical compositions, and methods of treating STAT3-mediated disorders.
- Dependent claims narrow the scope by specifying particular substituents and therapeutic indications, providing layered protection and fallback positions.
- The breadth of the patent is significant due to the encompassing nature of the Markush structure and the wide range of potential STAT3-mediated disorders.
- The STAT3 inhibitor patent landscape is competitive, with multiple entities developing small molecules, peptides, and nucleic acid-based therapies, necessitating rigorous freedom-to-operate analyses.
FAQs
-
What specific types of cancers are covered by Patent 10,688,060?
The patent broadly covers "STAT3-mediated disorders," which includes various cancers. Dependent claims refine this to specific cancer types such as leukemias, lymphomas, and solid tumors.
-
Does Patent 10,688,060 prevent the development of any STAT3 inhibitor?
It prevents the development and commercialization of STAT3 inhibitors that fall within the specific scope of its claims. Freedom-to-operate analyses are required to determine if a particular inhibitor infringes on this patent.
-
Can a generic drug manufacturer challenge the validity of this patent?
Yes, generic drug manufacturers or other interested parties can challenge the validity of a patent through various legal mechanisms, such as post-grant review, if they believe it was improperly granted.
-
What is the primary chemical scaffold claimed in Patent 10,688,060?
The primary chemical scaffold claimed is a substituted pyrazolo[3,4-d]pyrimidine.
-
Who is the assignee of Patent 10,688,060?
The assignee of United States Patent 10,688,060 is The Regents of the University of California.
Citations
[1] The Regents of the University of California. (2020). STAT3 inhibitors and methods of use thereof (U.S. Patent No. 10,688,060). Washington, DC: U.S. Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
